search

Active clinical trials for "Thrombocytopenia"

Results 61-70 of 643

Immunomodulation With Eltrombopag in ITP

Primary Immune Thrombocytopenia (ITP)

The study aims to investigate immunomodulatory effects of eltrombopag combined with dexamethasone in young and midlife adult patients with newly diagnosed primary Immune thrombocytopenia (ITP).

Recruiting23 enrollment criteria

TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years

Primary Immune Thrombocytopenic Purpura

This multi-center study aims to study the efficacy of TPO-RAs' transformation in Chinese ITP patients older than 14 years. This study will be conducted in ITP patients who had not responded to first-line in the previous treatment .

Recruiting12 enrollment criteria

Herombopag for Chemotherapy-induced Thrombocytopenia

Chemotherapy-induced ThrombocytopeniaHerombopag

To evaluate the efficacy and safety of Herombopag to treat chemotherapy-induced thrombocytopenia in Solid Tumors

Recruiting23 enrollment criteria

Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment...

Bone Marrow Failure SyndromeCongenital Amegakaryocytic Thrombocytopenia5 more

This phase II trial tests whether treosulfan, fludarabine, and rabbit antithymocyte globulin (rATG) work when given before a blood or bone marrow transplant (conditioning regimen) to cause fewer complications for patients with bone marrow failure diseases. Chemotherapy drugs, such as treosulfan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fludarabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. rATG is used to decrease the body's immune response and may improve bone marrow function and increase blood cell counts. Adding treosulfan to a conditioning regimen with fludarabine and rATG may result in patients having less severe complications after a blood or bone marrow transplant.

Recruiting133 enrollment criteria

Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

Immune ThrombocytopeniaAutoantibodies2 more

This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult Immune Thrombocytopenia (ITP) patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag treatment.

Recruiting26 enrollment criteria

TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary...

Primary Immune Thrombocytopenia (ITP)

This multicenter randomized, open-label study aime to compare the efficacy and safety of TPO-RAs combining anti-CD 20 monoclonal antibody with TPO-RAs in China pediatric ITP patients .This study will be conducted in persistent or chronic pediatric ITP patients who had not responded to or had relapsed after previous hormone treatment.

Recruiting26 enrollment criteria

Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic...

Blood CancerRefractory Immune Cytopenias

The purpose of this study is to find out whether isatuximab is an effective treatment for people who developed immune cytopenias/ICs after allogeneic hematopoietic cell transplant/allo-HCT.

Recruiting39 enrollment criteria

Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy

Malignant Tumors of the Digestive SystemTrombocitopenia

To evaluate the efficacy and safety of hetrombopag in the treatment of thrombocytopenia after chemotherapy in patients with digestive system malignant tumors

Recruiting25 enrollment criteria

A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated...

Previously Treated Primary Immune Thrombocytopenia

TE-ITP study: Compare the efficacy and safety of optimized rhTPO treatment versus Eltrombopag treatment in previously treated primary immune thrombocytopenia patients.

Recruiting14 enrollment criteria

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown...

Clonal Cytopenia of Undetermined Significance

This phase II trial tests how well canakinumab works to prevent progression to cancer in patients with clonal cytopenias of unknown significance (CCUS). CCUS is a blood condition defined by a decrease in blood cells. Blood cells are composed of either red blood cells, white blood cells, or platelets. In patients with CCUS, blood counts have been low for a long period of time. Patients with CCUS also have a mutation in one of the genes that are responsible for helping blood cells develop. The combination of genetic mutations and low blood cell counts puts patients with CCUS at a higher risk to develop blood cancers in the future. This transformation from low blood cell counts to cancer may be caused by inflammation in the body. Canakinumab is a monoclonal antibody that may block inflammation in the body by targeting a specific antibody called the anti-human interleukin-1beta (IL-1beta).

Recruiting49 enrollment criteria
1...678...65

Need Help? Contact our team!


We'll reach out to this number within 24 hrs